<i>Lactobacillus reuteri</i> MJM60668 Prevent Progression of Non-Alcoholic Fatty Liver Disease through Anti-Adipogenesis and Anti-Inflammatory Pathway
Non-alcoholic fatty liver disease (NALFD) is a disease characterized by liver steatosis. The liver is a key organ involved in the metabolism of fat, protein, and carbohydrate, enzyme activation, and storage of glycogen, which is closely related to the intestine by the bidirectional relation of the g...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/10/11/2203 |
| _version_ | 1797467165360652288 |
|---|---|
| author | Pia Werlinger Huong Thi Nguyen Mingkun Gu Joo-Hyung Cho Jinhua Cheng Joo-Won Suh |
| author_facet | Pia Werlinger Huong Thi Nguyen Mingkun Gu Joo-Hyung Cho Jinhua Cheng Joo-Won Suh |
| author_sort | Pia Werlinger |
| collection | DOAJ |
| description | Non-alcoholic fatty liver disease (NALFD) is a disease characterized by liver steatosis. The liver is a key organ involved in the metabolism of fat, protein, and carbohydrate, enzyme activation, and storage of glycogen, which is closely related to the intestine by the bidirectional relation of the gut-liver axis. Abnormal intestinal microbiota composition can affect energy metabolism and lipogenesis. In this experiment, we investigated the beneficial effect of <i>Lactobacillus reuteri</i> MJM60668 on lipid metabolism and lipogenesis. C57BL/6 mice were fed a high-fat diet (HFD) and orally administrated with MJM60668. Our results showed that mice treated with MJM60668 significantly decreased liver weight and liver/body weight ratio, without affecting food intake. Serum levels of ALT, AST, TG, TCHO, and IL-1β in mice fed with MJM60668 were decreased compared to the HFD group. Investigation of gene and protein expression on the lipogenesis and lipid metabolism showed that the expression of ACC, FAS, and SREBP was decreased, and PPARα and CPT was increased. Furthermore, an increase of adiponectin in serum was shown in our experiment. Moreover, serum IL-1β level was also significantly decreased in the treated mice. These results suggested that MJM60668 can strongly inhibit lipogenesis, enhance fatty acid oxidation, and suppress inflammation. Additionally, supplementation of MJM60668 increased the proportion of <i>Akkermansiaceae</i> and <i>Lachnospiracea</i>, confirming a potential improvement of gut microbiota, which is related to mucus barrier and decrease of triglycerides levels. |
| first_indexed | 2024-03-09T18:49:47Z |
| format | Article |
| id | doaj.art-42138558b15f4fd8a7d5f261580e6e1b |
| institution | Directory Open Access Journal |
| issn | 2076-2607 |
| language | English |
| last_indexed | 2024-03-09T18:49:47Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj.art-42138558b15f4fd8a7d5f261580e6e1b2023-11-24T05:57:24ZengMDPI AGMicroorganisms2076-26072022-11-011011220310.3390/microorganisms10112203<i>Lactobacillus reuteri</i> MJM60668 Prevent Progression of Non-Alcoholic Fatty Liver Disease through Anti-Adipogenesis and Anti-Inflammatory PathwayPia Werlinger0Huong Thi Nguyen1Mingkun Gu2Joo-Hyung Cho3Jinhua Cheng4Joo-Won Suh5Interdisciplinary Program of Biomodulation, Myongji University, Yongin 17058, KoreaInterdisciplinary Program of Biomodulation, Myongji University, Yongin 17058, KoreaInterdisciplinary Program of Biomodulation, Myongji University, Yongin 17058, KoreaMyongji Bioefficacy Research Center, Myongji University, Yongin 17058, KoreaInterdisciplinary Program of Biomodulation, Myongji University, Yongin 17058, KoreaInterdisciplinary Program of Biomodulation, Myongji University, Yongin 17058, KoreaNon-alcoholic fatty liver disease (NALFD) is a disease characterized by liver steatosis. The liver is a key organ involved in the metabolism of fat, protein, and carbohydrate, enzyme activation, and storage of glycogen, which is closely related to the intestine by the bidirectional relation of the gut-liver axis. Abnormal intestinal microbiota composition can affect energy metabolism and lipogenesis. In this experiment, we investigated the beneficial effect of <i>Lactobacillus reuteri</i> MJM60668 on lipid metabolism and lipogenesis. C57BL/6 mice were fed a high-fat diet (HFD) and orally administrated with MJM60668. Our results showed that mice treated with MJM60668 significantly decreased liver weight and liver/body weight ratio, without affecting food intake. Serum levels of ALT, AST, TG, TCHO, and IL-1β in mice fed with MJM60668 were decreased compared to the HFD group. Investigation of gene and protein expression on the lipogenesis and lipid metabolism showed that the expression of ACC, FAS, and SREBP was decreased, and PPARα and CPT was increased. Furthermore, an increase of adiponectin in serum was shown in our experiment. Moreover, serum IL-1β level was also significantly decreased in the treated mice. These results suggested that MJM60668 can strongly inhibit lipogenesis, enhance fatty acid oxidation, and suppress inflammation. Additionally, supplementation of MJM60668 increased the proportion of <i>Akkermansiaceae</i> and <i>Lachnospiracea</i>, confirming a potential improvement of gut microbiota, which is related to mucus barrier and decrease of triglycerides levels.https://www.mdpi.com/2076-2607/10/11/2203<i>Lactobacillus reuteri</i> MJM60668NAFLDanti-adipogenesisprobioticsmicrobiota |
| spellingShingle | Pia Werlinger Huong Thi Nguyen Mingkun Gu Joo-Hyung Cho Jinhua Cheng Joo-Won Suh <i>Lactobacillus reuteri</i> MJM60668 Prevent Progression of Non-Alcoholic Fatty Liver Disease through Anti-Adipogenesis and Anti-Inflammatory Pathway Microorganisms <i>Lactobacillus reuteri</i> MJM60668 NAFLD anti-adipogenesis probiotics microbiota |
| title | <i>Lactobacillus reuteri</i> MJM60668 Prevent Progression of Non-Alcoholic Fatty Liver Disease through Anti-Adipogenesis and Anti-Inflammatory Pathway |
| title_full | <i>Lactobacillus reuteri</i> MJM60668 Prevent Progression of Non-Alcoholic Fatty Liver Disease through Anti-Adipogenesis and Anti-Inflammatory Pathway |
| title_fullStr | <i>Lactobacillus reuteri</i> MJM60668 Prevent Progression of Non-Alcoholic Fatty Liver Disease through Anti-Adipogenesis and Anti-Inflammatory Pathway |
| title_full_unstemmed | <i>Lactobacillus reuteri</i> MJM60668 Prevent Progression of Non-Alcoholic Fatty Liver Disease through Anti-Adipogenesis and Anti-Inflammatory Pathway |
| title_short | <i>Lactobacillus reuteri</i> MJM60668 Prevent Progression of Non-Alcoholic Fatty Liver Disease through Anti-Adipogenesis and Anti-Inflammatory Pathway |
| title_sort | i lactobacillus reuteri i mjm60668 prevent progression of non alcoholic fatty liver disease through anti adipogenesis and anti inflammatory pathway |
| topic | <i>Lactobacillus reuteri</i> MJM60668 NAFLD anti-adipogenesis probiotics microbiota |
| url | https://www.mdpi.com/2076-2607/10/11/2203 |
| work_keys_str_mv | AT piawerlinger ilactobacillusreuteriimjm60668preventprogressionofnonalcoholicfattyliverdiseasethroughantiadipogenesisandantiinflammatorypathway AT huongthinguyen ilactobacillusreuteriimjm60668preventprogressionofnonalcoholicfattyliverdiseasethroughantiadipogenesisandantiinflammatorypathway AT mingkungu ilactobacillusreuteriimjm60668preventprogressionofnonalcoholicfattyliverdiseasethroughantiadipogenesisandantiinflammatorypathway AT joohyungcho ilactobacillusreuteriimjm60668preventprogressionofnonalcoholicfattyliverdiseasethroughantiadipogenesisandantiinflammatorypathway AT jinhuacheng ilactobacillusreuteriimjm60668preventprogressionofnonalcoholicfattyliverdiseasethroughantiadipogenesisandantiinflammatorypathway AT joowonsuh ilactobacillusreuteriimjm60668preventprogressionofnonalcoholicfattyliverdiseasethroughantiadipogenesisandantiinflammatorypathway |